Volitionrx limited announces full fiscal year 2020 financial results and business update

Launched first product, the nu.q® vet cancer screening test and recorded first revenue from sales of a commercial product engaged diagnostic oncology cro llc to conduct u.s. regulatory clinical trial for non-hodgkin's lymphoma expanded research program for the use of nu.q® technology in netosis (covid-19 and sepsis) strengthened intellectual property portfolio purchased and opened first production facility strongest-ever cash position following a public offering in february 2021 austin, texas, march 22, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition") today announced financial results and a business update for the full fiscal year ended december 31, 2020. volition management will host a conference call tomorrow, march 23 at 8:00 a.m.
VNRX Ratings Summary
VNRX Quant Ranking